PP
PRAX icon

PDT Partners’s Praxis Precision Medicines PRAX Stock Holding History

PDT Partners’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,080
Closed -$37K – 838
2022
Q3 		$37K Buy
+1,080
New +$53.8K 0.01% 814

Other funds holding PRAX

Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

PDT Partners's PRAX Position: Q4 2022 in Review

PDT Partners sold out of Praxis Precision Medicines (PRAX) in Q4 2022, closing a stake of 1,080 shares — an estimated $37K sold.

PDT Partners first reported a position in PRAX in Q3 2022 and held it in 1 quarter. The position peaked at $37K in Q3 2022. 103 funds tracked by Wall St. Rank hold PRAX as of Q4 2022.

  • PDT Partners reported no remaining Praxis Precision Medicines position as of Q4 2022 after selling out during the quarter.
  • PDT Partners sold 1,080 Praxis Precision Medicines shares in Q4 2022, an estimated $37K.
  • PDT Partners first reported a position in Praxis Precision Medicines in Q3 2022 and held it in 1 quarter.
  • PDT Partners's Praxis Precision Medicines position peaked at $37K in Q3 2022.
  • 103 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q4 2022.

Based on PDT Partners's 13F filing for Q4 2022, filed 14 Feb 2023.